NICE guidelines for management of chest pain

Jump to navigation Jump to search

Chest pain Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chest pain from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Chest Pain in Pregnancy

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

NICE guidelines for management of chest pain On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on NICE guidelines for management of chest pain

CDC on NICE guidelines for management of chest pain

NICE guidelines for management of chest pain in the news

Blogs on NICE guidelines for management of chest pain

to Hospitals Treating NICE guidelines for management of chest pain

Risk calculators and risk factors for NICE guidelines for management of chest pain

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Sara Zand, M.D.[2] Cafer Zorkun, M.D., Ph.D. [3]; Priyamvada Singh, M.B.B.S. [4]

Overview

In the 2016 update of the stable chest pain guideline, National Institute for Health and Clinical Excellence (NICE) has dramatically changed its approach to new-onset stable chest pain aiming to find a more cost-effective strategy including NO use of pretest probability risk scores or NO use of functional tests such as stress echocardiography, as a first-line investigation. The suggestion is to use CT coronary angiography in patients with typical or atypical chest pain. In addition, there is no recommendation for any diagnostic testing if chest pain is non-anginal. Also, perfusion imaging is recommended in the setting of uncertainty about the functional significance of coronary lesions. However, the recommendation of the European Society of Cardiology (ESC—2013) is performing functional tests as the initial investigation.

NICE Guidelines for the Management of Patients with Acute Chest Pain[1]

  • Pain in the chest and/or other areas (for example, the arms, back or jaw) lasting longer than 15 minutes ·
  • Chest pain associated with nausea and vomiting, marked sweating, breathlessness, or particularly a combination of these ·
  • Chest pain associated with hemodynamic instability ·
  • New onset chest pain, or abrupt deterioration in previously stable angina, with recurrent chest pain occurring frequently and with little or no exertion, and with episodes often lasting longer than 15 minutes
  • If the patient is currently pain-free, but had chest pain in the last 12 hours, and resting 12-lead ECG is abnormal or not available or develops further chest pain after recent (confirmed or suspected) ACS, evaluation about ACS is warranted.
  • Management of ACS:
  • Assessment of patients with suspected ACS in the hospital:
  • Use of high-sensitivity troponin tests is not recommended, if ACS is not suspected
  • For patients at high or moderate risk of MI (as indicated by a validated tool), performing high sensitivity troponin tests is reasonable.
  • For patients at low risk of MI :
  • Performing a second high-sensitivity troponin test
  • Considering a single high-sensitivity troponin test only at presentation to rule out NSTEMI , if the first troponin test is below the lower limit of detection (negative).
  • A detectable troponin on the first high-sensitivity test does not necessary for patients with confirmed MI.
  • For diagnose of ACS use of biochemical markers such as natriuretic peptides and high-sensitivity C-reactive protein are not recommended.

.

  • Factors should be considered for interpreting high-sensitivity troponin:
  • the clinical presentation
  • the time from onset of symptoms
  • the resting 12-lead ECG findings
  • the pre-test probability of NSTEMI
  • the length of time since the suspected ACS
  • the probability of chronically elevated troponin levels in some patients
  • that 99th percentile thresholds for troponin I and T may differ between sexes.

Management of patients with stable chest pain

Clinical assessment

  • Assessment of the typicality of chest pain as follows:
  • Presence of three of the features below is defined as typical angina.

· Presence of two of the three features below is defined as atypical angina. · Presence of one or none of the features below is defined as non-anginal chest pain. Anginal pain is:

differently in men and women in ethnic groups.


  • Consider aspirin only if the chest pain is likely to be stable angina until a diagnosis is made.
  • If the patient is already taking aspirin or is allergic to it, do not offer additional aspirin.
  • The Guideline Development Group emphasized that the recommendations in this guideline are to make a diagnosis of chest pain, not to screen for CAD.
  • Most people diagnosed with non-anginal chest pain after clinical assessment need no further diagnostic testing. However in a very small number of

people, there are remaining concerns that the pain could be ischaemic.

contraindications (for example, disabilities, frailty, limited ability to exercise) when deciding on the imaging method.

adenosine or dipyridamole for first-pass contrast-enhanced MR perfusion.

wall motion abnormalities.

disease in the epicardial coronary arteries.

NICE Guidelines for the Management of Patients with Acute Chest Pain [1]

Investigation and diagnosis of acute chest pain in hospital

 
 
 
 
 
 
 
 
Assessment of acute chest pain in hospital
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal resting ECG or non-diagnostic
 
 
 
 
ECG changes consistent with NSTEMI
 
 
 
 
ECG changes consistent with STEMI
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low risk patient with undetectable hs-troponin level: Reassurance, discharge
 
Consider ACS by clinical judgment even in the presence of normal ECG
  • Repeat hs-troponin level after 3 hours of arrival in hospital while diagnosis is not clear
  • Serial ECG taken and clinically assessment of patient and considering the ECG changes
  • Investigation regarding other life-threatening causes of chest pain
  • NO need for routin non-invasive cardiac imaging or EX-ECG for initial evaluation
  • Consider other differential diagnosis

  • Consider hs-troponin level 3 hours after initiation of symptoms
  • Consider an alternative diagnosis
 
 
NSTEMI, ACS Guideline follow-up
 
 
 
STEMI Guideline follow-up
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hs-troponin concentration on arrival and at 3 hours bellow the cut-off measurement: Low risk patient, discharge
 
 
hs-troponin concentration on arrival and at 3 hours higher than cut-off measurement
 
Diagnostic criteria for MI
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes:
 
 
NO:
  • Consider CXR or Chest CT scan for evaluation of alternative diagnosis
  •  
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    The above algorithm adopted from 2016 NICE Guideline

    NICE guidelines for the management of patients with stable chest pain[1]

    National Institute for Health and Clinical Excellence (NICE) has dramatically changed its guideline on approach to stable chest pain aiming to find a more cost-effective strategy including NO use of pretest probability risk scores or NO use of functional tests, such as stress echocardiography, as a first-line investigation in patients with new-onset stable chest pain. The suggestion is to use CT coronary angiography in the majority of patients. However, the recommendation of the European Society of Cardiology (ESC—2013) is functional tests as the initial investigation.[2]



     
     
     
    Assessment and detailed history
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Non anginal aspect of chest pain without cardiac risk factors or clinical suspicious
     
     
     
    Typical or atypical anginal in clinical assessment
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Indentify other causes of chest pain
    • Only consider CXR if other causes are suspected
     
     
     
    Consider resting ECG
  • Obtaining blood sample testing
  • Consider ASA while waiting for the preparation of test results
  • Evaluation of other causes of chest pain including hypertrophic cardiomyopathy in the setting of typical chest pain and low likelihood of CAD
  •  
     
     
    The above algorithm adopted from 2016 NICE Guideline





     
     
     
    Consider 64 slice (or obove) Coronary CT Angiography in the presence of:
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Consider non-invasive functional imaging in the presence of:
     
     
     
    Consider stable angina in the presence of obstructive CAD on coronary CT angiography or reversible ischemia on functional imaging study
  • Consider other causes of chest pain in the absence of above findings

  •  
     
     
     
    Stable chest pain:

    ❑ Typical stable angina symptoms:

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Stable angina is unlikely if chest pain is:

    ❑ Not related to the activity
    ❑ Very prolonged or continuous
    ❑ Exacerbated by inspiration
    ❑ Associated with dizziness, palpitations, tingling, difficulty in swallowing

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    ECG changes associated with CAD:

    LBBB
    ❑ Pathologic Q waves
    ❑ ST-T abnormalities

     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Non-invasive functional imaging study for evaluation of myocardial ischemia:

    Myocardial perfusion scintigraphy with single photon emission CT ( with adenosin, dipyridamole, dobutamine
    Stress echocardiography (with exercise or dobutamine
    ❑First pass contrast enhanced MR perfusion with adenosine or dipyridamole
    ❑ MR imaging with exercise or dobutamine
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Definition of significant CAD:

    ❑Coronary CT angiography:

    ❑ Factors associated with intensifying ischemia in the lesions less than 50%

    ❑ Factors associated reduced ischemia in significant lesion ≥70 %:

    • Well developed collateral supply
    • Small ischemia region of myocardium due to fiat ally location of lesion
    , old infarction the territory of coronary supply
     
     
     
     
    The above algorithm adopted from 2016 NICE Guideline

    References

    1. 1.0 1.1 1.2 Carrabba N, Migliorini A, Pradella S, Acquafresca M, Guglielmo M, Baggiano A, Moscogiuri G, Valenti R (2018). "Old and New NICE Guidelines for the Evaluation of New Onset Stable Chest Pain: A Real World Perspective". Biomed Res Int. 2018: 3762305. doi:10.1155/2018/3762305. PMC 6250018. PMID 30533431.
    2. Timmis A, Roobottom CA (July 2017). "National Institute for Health and Care Excellence updates the stable chest pain guideline with radical changes to the diagnostic paradigm". Heart. 103 (13): 982–986. doi:10.1136/heartjnl-2015-308341. PMID 28446550.


    Template:WikiDoc Sources